Search results for "myocardial infarction."

showing 10 items of 1011 documents

Small, dense low-density-lipoproteins and the metabolic syndrome.

2006

Small, dense low-density-lipoproteins (LDL) are associated with increased risk for cardiovascular diseases and diabetes mellitus and a reduction in LDL size has been reported in patients with coronary and non-coronary forms of atherosclerosis. LDL size has been accepted as an important predictor of cardiovascular events and progression of coronary artery disease as well as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Small, dense LDL, with elevated triglyceride levels and low HDL-cholesterol concentrations, constitute the 'atherogenic lipoprotein phenotype (ALP)', a form of atherogenic dyslipidemia that is a feature of type …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMyocardial InfarctionCoronary DiseaseType 2 diabetesmetabolic syndromeCoronary artery diseasechemistry.chemical_compoundEndocrinologyatherosclerosipreventionRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansParticle SizeRisk factorNational Cholesterol Education ProgramTriglycerideVascular diseasebusiness.industrydense LDLsmallAtherosclerosismedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2chemistrydiabeteCardiologylipids (amino acids peptides and proteins)Metabolic syndromebusiness
researchProduct

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program

2020

Diabetes is associated with a substantially increased risk of all-cause death, mainly driven by cardiovascular (CV) mortality. Furthermore, diabetes is associated with poorer outcomes after acute myocardial infarction (AMI) (1). Impaired glomerular filtration rate (GFR) is also associated with an increased risk of CV mortality (2). However, whether diabetes still confers a higher risk of mortality in patients with impaired GFR remains unknown. The aim of this study was to assess the long-term prognostic significance of both diabetes and renal impairment in two prospective nationwide cohorts of AMI patients: FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarc…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Renal function030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIntensive careInternal MedicinemedicineRisk of mortality030212 general & internal medicineMyocardial infarction10. No inequalityComputingMilieux_MISCELLANEOUSAdvanced and Specialized NursingFramingham Risk Scorebusiness.industrymedicine.disease3. Good healthHeart failureCardiologybusinessKidney disease
researchProduct

Smoking-induced preconditioning: acute, but not chronic, smoking paradoxically protects the endothelium from ischemia and reperfusion

2013

medicine.medical_specialtyEndotheliumbusiness.industryIschemiamedicine.diseasemedicine.disease_causeAscorbic acidReperfusion therapymedicine.anatomical_structureInternal medicinemedicineCardiologyIschemic preconditioningMyocardial infarctionEndothelial dysfunctionCardiology and Cardiovascular MedicinebusinessOxidative stressEuropean Heart Journal
researchProduct

Exercise cardiac power and the risk of myocardial infarction and fatal coronary heart disease events in men.

2021

medicine.medical_specialtyEpidemiologybusiness.industryInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular Medicinemedicine.diseasebusinessCoronary heart diseaseEuropean journal of preventive cardiology
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Cross-country skiing and the risk of acute myocardial infarction: A prospective cohort study

2019

medicine.medical_specialtyExercise ToleranceCross countryEpidemiologybusiness.industryMyocardial InfarctionMEDLINEmedicine.diseaseRisk FactorsSkiingEmergency medicinemedicineHumansProspective StudiesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessProspective cohort studyEuropean Journal of Preventive Cardiology
researchProduct

Platelet Function Tests and Coronary Heart Disease

1984

It is well known that the formation of a platelet aggregate is the first step in an arterial thrombotic process.

medicine.medical_specialtyFramingham Risk ScoreEndotheliumPlatelet aggregationbusiness.industryeducationmedicine.diseaseCoronary heart diseasestomatognathic diseasesmedicine.anatomical_structurePlatelet function testPlatelet adhesivenessInternal medicinemedicineCardiologyPlateletMyocardial infarctionbusiness
researchProduct

013 Pre-infarction angina and cardiovascular complications in non ST segment elevation myocardial infarction: Data from the RICO survey

2010

BackgroundThe presence of preinfarction angina (PIA) has been shown to confer cardioprotection after ST segment elevation myocardial infarction (MI). However, the impact of PIA in non ST segment elevation (NSTEMI) remains to be determined.Patients and MethodsFrom the obseRvatoire des Infarctus de Côte d’Or (RICO) survey, 1541 consecutive patients admitted in intensive care unit with a first NSTEMI were included in the study. Patients who experienced chest pain 1) and 30-day mortality were collected.ResultsAmong the 1541 patients included in the study, 693 patients presented PIA. Baseline clinical characteristics were similar for the 2 groups. There was no significant difference for the GRAC…

medicine.medical_specialtyFramingham Risk Scorebusiness.industryInfarctionmedicine.diseaseChest painIntensive care unitlaw.inventionAnginalawHeart failureInternal medicinemedicineCardiologyST segmentMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Randomised clinical trials: a source of ethical dilemmas

2001

Clinical trials give rise to ethical dilemmas, especially in the acutely ill, but we take issue with two points raised in a recent comment on a specific acute myocardial infarction (AMI) trial. The commentators judged that the trial most likely could, and therefore should, have been terminated much earlier. By analysing the problem statistically we arrive at results that go against their intuitive judgment—they also see it as mandatory to update the patient Information sheet as trial results accrue and trends begin to emerge. In our view, interpreting subtle trends and borderline p-values must rest with data monitoring boards, not patients. Moreover, patients with AMI or in other medical em…

medicine.medical_specialtyHealth (social science)medicine.medical_treatmentAt the Coalface: Medical Ethics in PracticeTreatment outcomeMyocardial InfarctionAlternative medicineHospital mortalityResearch EthicsArts and Humanities (miscellaneous)Informed consentAngioplastymedicineHumansEthics MedicalThrombolytic TherapyHospital MortalityMyocardial infarctionIntensive care medicineRandomized Controlled Trials as TopicInformed Consentbusiness.industryPatient SelectionHealth PolicyAngioplastyCoronary Care Unitsmedicine.diseasehumanitiesClinical trialIssues ethics and legal aspectsTreatment OutcomeClinical researchEthics ClinicalData Interpretation StatisticalMedical emergencybusinessJournal of Medical Ethics
researchProduct